1021869-58-8

Basic information

• Product Name: methyl 4-chloro-2-((furan-2-ylmethyl)amino)-5-(N-methylsulfamoyl)benzoate
• Synonyms: methyl 4-chloro-2-((furan-2-ylmethyl)amino)-5-(N-methylsulfamoyl)benzoate
• CAS NO: 1021869-58-8
• Molecular Weight: 358.803
• Mol File: 1021869-58-8.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: methyl 4-chloro-2-((furan-2-ylmethyl)amino)-5-(N-methylsulfamoyl)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 4-chloro-2-((furan-2-ylmethyl)amino)-5-(N-methylsulfamoyl)benzoate(1021869-58-8)
• EPA Substance Registry System: methyl 4-chloro-2-((furan-2-ylmethyl)amino)-5-(N-methylsulfamoyl)benzoate(1021869-58-8)

Safety Data

• Hazardous Substances Data: 1021869-58-8(Hazardous Substances Data)

Upstream product

• 67-56-1 methanol 
• 85414-64-8 4-chloro-5-(N-cyclopropylsulfamoyl)-2-((furan-2-ylmethyl)amino)benzoic acid 
• 446-30-0 4-chloro-2-fluorobenzoic acid 
• 56447-54-2 4-chloro-2-fluoro-5-chlorosulfonylbenzoic acid 
• 186581-53-3 diazomethane 
• 54-31-9 4-chloro-2-furfurylamino-5-sulfamoyl-benzoic acid 

Downstream Products

• 85414-64-8 4-chloro-5-(N-cyclopropylsulfamoyl)-2-((furan-2-ylmethyl)amino)benzoic acid 

Relevant articles and documents

Design, synthesis, and biological evaluation of furosemide analogs as therapeutics for the proteopathy and immunopathy of Alzheimer's disease

β-Amyloid (Aβ) triggered proteopathic and immunopathic processes are a postulated cause of Alzheimer's disease (AD). Monomeric Aβ is derived from amyloid precursor protein, whereupon it aggregates into various assemblies, including oligomers and fibrils, which disrupt neuronal membrane integrity and induce cellular damage. Aβ is directly neurotoxic/synaptotoxic, but may also induce neuroinflammation through the concomitant activation of microglia. Previously, we have shown that furosemide is a known anthranilate-based drug with the capacity to downregulate the proinflammatory microglial M1 phenotype and upregulate the anti-inflammatory M2 phenotype. To further explore the pharmacologic effects of furosemide, this study reports a series of furosemide analogs that target both Aβ aggregation and neuroinflammation, thereby addressing the combined proteopathic-immunopathic pathogenesis of AD. Forty compounds were synthesized and evaluated. Compounds 3c, 3g, and 20 inhibited Aβ oligomerization; 33 and 34 inhibited Aβ fibrillization. 3g and 34 inhibited the production of TNF-α, IL-6, and nitric oxide, downregulated the expression of COX-2 and iNOS, and promoted microglial phagocytotic activity, suggesting dual activity against Aβ aggregation and neuroinflammation. Our data demonstrate the potential therapeutic utility of the furosemide-like anthranilate platform in the development of drug-like molecules targeting both the proteopathy and immunopathy of AD.

AQUAPORIN MODULATORS AND METHODS OF USING THEM FOR THE TREATMENT OF EDEMA AND FLUID IMBALANCE

Compounds, including 3-carboxy aryl sulfonamide compounds, which agonize or antagonize aquaporin channels and methods of using them to treat disorders or diseases mediated by aquaporins.